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Abstract
Objective: Trauma during dental surgery is a predisposing factor for bisphosphonates (BP)-related osteonecrosis 
of the jaws (BRONJ). However, about 40% of cases of BRONJ are not related to dental invasive procedures, be-
ing probably associated to endodontic or periodontal infections. Extraction of non-treatable teeth is considered a 
reliable choice, to improve symptoms and to reduce the risk of BRONJ. 
Here we report our experience of tooth extractions in patients  under oral or intravenous BP therapy.
Study Design: Two-hundred and seventeen patients (38 males, 179 females; mean age 68.72 ± 11.26  years, range 
30 to 83 years) under BP therapy received 589 tooth extractions at the Unit of Oral Medicine, Pathology and 
Laser-assisted Surgery of the University of Parma, Italy, between June 2006 and December 2010. Ninety five 
patients were under BP therapy for oncological disease (multiple myeloma (MM): 23; bone metastases (BM): 
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72) and 122 patients for non oncological diseases: 119 osteoporosis (OP), 2 rheumatoid arthritis (RA) and 1 Paget’s 
disease (PD). The mean duration of BP was of 35 months. 
Antibiotic treatment was administered three days before and 2 weeks after tooth extractions. Patients were addi-
tionally treated with low level laser therapy (LLLT) through Nd:YAG laser (1064 nm – power 1.25 W; frequency 15 
Hz; fibre diameter: 320 μm), 5 application of 1 minute each. Patients were evaluated 3 days and once a week for 2 
months after the extractions and every time they received LLLT. Mean follow-up was 15 months (ranging from 4 
to 31 months). 
Results: In a total of 589 extractions (285 mandibular, 304 maxillary) performed, a minimal bone exposure was 
observed in 5 cases, treated with Er:YAG laser vaporization and than healed. 
Conclusions: Our experience supports the hypothesis that the association of antibiotic treatment and LLLT can be 
effective in preventing ONJ after tooth extractions in patients under BPT.
Key words: Nd:YAG laser, low level laser therapy, tooth extractions, bisphosphonates, jaws osteonecrosis.
Introduction
The avascular osteonecrosis of the jaws (ONJ) associ-
ated with bisphosphonates (BP) therapy was firstly de-
scribed in 2003 (1). Patients under oral BP have a lower 
prevalence of ONJ (0.01% to 0.04%) than those treated 
intravenously (0.8% to 12%). In particular, ONJ seems 
to occur most frequently in patients using BP for mul-
tiple myeloma (MM), bone metastases (BM) and oste-
oporosis (OP) (2).
Trauma during dental surgery is a well-recognised pre-
disposing factor for BP-associated ONJ (BRONJ): if 
60% of cases occur after oral surgery including tooth 
extractions, about 40% of BRONJ is not related to den-
tal procedures (3,4). In their review, Marx et al. iden-
tified several co-morbidity factors such as presence of 
periodontal diseases, decays and dental abscesses. Age 
and prolonged BPT have also been associated with an 
increased risk of BRONJ (5). 
Main clinical BRONJ manifestations include presence 
of persistent bone exposures, possibly associated with 
presence of fistulas, purulent discharge, pain, paraes-
thesia, loss of teeth and mandibular fractures. About 
65% of patients presents mandibular lesions (6).
Ruggiero et al. proposed a clinical staging system for 
BRONJ, which recognises 3 stages: stage I - asympto-
matic exposed bone and no soft tissues infection; stage 
II - exposed bone, pain, infection and swelling of the 
soft tissue; stage III - exposed bone, pain, pathologi-
cal fractures and soft tissue infections (7). Presence of 
avascular necrotic bone, bacterial and fungal colonies 
as well as abundant inflammatory infiltration are typi-
cal histopathological findings (8).
BP inhibit turnover and repairing capacity of the bone 
after micro damages (9), reducing also the epithelial 
cells proliferation rate in vitro, via the reduction of far-
nesyl diphosphate synthetase, and exhibiting also an-
tiangiogenetic properties by decreasing the production 
of vascular endothelial growth factor (VEGF) (10,11), 
thus determining important effects on both quality and 
quantity of bone vascularization, possibly altering the 
response to trauma and infections (12).
Several authors studied the relationship between 
BRONJ and dental procedures, and proposed clinical 
protocol for preventing the occurrence of (13,14). How-
ever, evidence-based guidelines for the management of 
dental extractions in patients under BP therapy (BPT) 
are still lacking.
Currently, low-level laser therapy (LLLT) is employed 
in a wide range of cutaneous, mucosal and bone disor-
ders with bio-modulative and analgesic purposes. 
We recently observed and reported the usefulness of 
Nd:YAG laser biostimulation associated with medical 
or surgical therapy in the management of BPT-associ-
ated ONJ. On the basis of the above mentioned results, 
we hypothesized that LLLT may also improve the post-
extractive healing process in patients under BP therapy 
(15,16).
Patient and Methods
Five-hundred eighty-nine tooth extractions were per-
formed in 217 patients (38 males, 179 females; mean age 
68.72 years, range 30 to 83 years) under BPT at the Unit 
of Oral Medicine, Oral Pathology and Laser-assisted 
Oral Surgery of the University of Parma, Italy, between 
June 2006 and December 2010. 
Two-hundred seventy-one tooth extractions were per-
formed in 95 cancer patients (23 multiple myeloma, 72 
Bone metastasis). In 87 cases administered BP drug was 
zoledronate, in 1 case zoledronate and pamidronate, in 
3 cases aledronate, in 1 case risedronate and in 3 cases 
aledronate and zoledronate. One hundred and twenty-
two non-cancer patients underwent 318 extractions. 
In 51 cases administered BP drug was aledronate, in 
24 clodronate, in 17 risedronate, in 30 cases different 
association of BPs.
Mean duration of BPT before the extractions was 17 
months for the oncological patients, 53 months for the 
osteoporotic patients (ranging from 1 to 92 months). 
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On the basis of medical conditions, the specialists sug-
gested BPT discontinuation for 2 months before and af-
ter tooth extractions in 49 Patients.
Twenty patients out of 217 were affected by BRONJ oc-
curring at a oral subsite not related with the area of den-
tal extraction.
For each patient were considered adjunctive pharmaco-
logical therapies and presence of risk factors for BRONJ 
such as smoking habit, diabetes, vascular diseases and 
renal failure. Orthopantomography and, in cases of ne-
cessity, intraoral radiographies were obtained for all 
patients. 
Tooth extractions were performed when no conven-
tional dental treatment would have been reliable, and 
particularly in case of: diffuse and symptomatic peri-
odontal and/or endodontic infections; destroying caries; 
complicated dental fractures. Five-hundred eighty-nine 
teeth were extracted under local anaesthesia, in agree-
ment with the oncologist and/or the general practitioner 
of each patient. All patients were informed about the 
individual risk of BRONJ occurrence after oral surgi-
cal procedures, and a written consensus was obtained 
in each case. 
One week before tooth extraction professional oral 
hygiene procedures were performed. Amoxicillin (2 
grams per day) was administered 3 days before and for 
2 weeks after tooth extractions until suture removal. 
Post-extractive sockets irrigations with povidone-iodine 
were administered. Mouthwashes with chlorhexidine 3 
times per day were recommended until complete mu-
cosal healing. 
Patients received LLLT (Nd:YAG laser, 1064 nm, Fide-
lis Plus, Fotona®, Slovenia – power:1.25 W; frequency: 
15 Hz; diameter of the fibre: 320 μm) which was admin-
istered in non-focused mode, at 2 mm of distance from 
the tissues, for 1 minute (power density: 1562.5 W/cm2, 
total fluence 7 J/cm2), repeated 5 times. Intra-operative 
LLLT was delivered in the post-extractive sockets once 
a week for 6 times. Patients were evaluated after 3 days 
and once a week for 2 months after tooth extraction. 
After this period, follow-up scheme included monthly 
clinical evaluations as well as radiological examination 
every six months (Table 1). 
Surgical procedures were performed according to the 
protocol of Parma University Hospital. 
Results
Five hundred eighty-nine dental extractions (285 man-
dibular, 304 maxillary) (Table 2) were performed. 150 
out of 589 dental extractions were performed through 
the use of mucoperiosteal flaps and osteotomy. Fifteen 
patients have had a delayed but complete healing of the 
post-extractive sockets in a maximun period of 8 weeks 
and a minimal bone exposure was observed after 5 
tooth extractions performed in cancer patients (4 male, 
1 female) among a total of 589, with an incidence about 
0,85% (Table 3).
Such post-extractive sites were characterized by the 
presence of small fragments (less than 3mm in the main 
size) of bone, partially covered by non-inflamed mu-
cosa. Pain and pus discharge were absent in all cases. 
Management of these complications was based on an-
tiseptic, adjunctive antibiotic therapies (amoxicillin, 2 
grams per day and metronidazole, 500 milligrams per 
day) and LLLT. 
Wounds closure was obtained within 2 months through 
a single intervention of curettage and vaporization with 
Er:YAG laser (2940 nm, 250 mJ, 20 Hz, VSP, Fluence 
50 J/cm2, Fidelis Plus, Fotona®, Slovenia) of the little 
bone residual fragments. Clinical data including risk 
factors and medical conditions of these patients are 
summarized in table 3.
     1 Systemic antibiotics (amoxicillin - 2 grams per day, 3 days before tooth extractions). 
     2 Intra-operative irrigations of the alveolar socket with povidone iodine solution + LLLT application (Nd:YAG laser: 1,25 W, 15 Hz – 1 minute for 5 times).  
     3 Systemic antibiotics (amoxicillin - 2 grams per day for 14 days until suture removal); mouthwashes with chlorhexidine and hydrogen peroxide (3 times per day). 
4 LLLT weekly applications for the first 6 weeks and additional applications until complete mucosal healing. 
     5 Monthly follow-up visits for the first 2 months, and then every 3 and 6 months. OPT after 6 and 12 months. 
Table 1. Clinical protocol used in the present study for tooth extractions in patients under BPT. 
LLLT = low level laser therapy.
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Primary disease Sites Maxilla/ Mandible Sites 
Oncological 
patients
Bone metastasis 209
Maxilla 94
Mandible 115
Multiple mieloma 62
Maxilla 36
Mandible 26
Non
Oncological 
patients
Osteoporosis 309
Maxilla 168
Mandible 141
Reumatoid arthritis 6
Maxilla 6
Mandible -
Paget’s disease 3
Maxilla -
Mandible 3
Table 2. Characteristics of extraction sites: number of extraction sites, primary 
disease and maxillary or mandibular localization. 
Patients SG PA PG BR RL
Age 75 y 73 y 63 y 75 y 58y 
Gender M M F M M
Pathology BM BM BM BM BM
BP Zoledronic acid Zoledronic acid Zoledronic acid Zoledronic acid Zoledronic acid 
BPT duration 
(months) 4 2 2 6 3
Site Maxilla Maxilla Maxilla Mandible Maxilla  
Complicated extraction No No No No No
BPT discontinuation No No No No No  
Smoke habit Yes No Yes No  No  
Diabetes Yes No Yes Yes No  
Corticosteroids therapy Yes Yes Yes Yes Yes
Other therapies 
Hormonal therapy; 
chemotherapy; 
oppioids
Chemotherapy; 
oral anticoagulants 
Hormonal therapy; 
chemotherapy 
Hormonal therapy; 
chemotherapy 
Hormonal therapy; 
chemotherapy 
Other extraction healed 1 0 1 0 0
Table 3. Clinical data of 5 patients with difficult healing after tooth extractions.
Discussion
Tooth extractions is a well known risk factor for BRONJ 
development, but an increasing of non-triggered forms 
has been reported in the literature (3). 
In an Italian multicentric study 205 out of 567 patients 
(36,2%), evaluated by Vescovi et al had a non-triggered 
bone exposure,  probably related to endodontic and/or 
periodontal infections (17). It can be hypothesized that 
the action of oral bacteria altogether with a decreased 
healing potential of the bone and soft tissues induced by 
BPT may favourite the development of BRONJ (18). 
Guidelines for the dental management of patients un-
der BPT recommend, in cases of infective odontogenic 
foci, to avoid dental surgery and suggest medical and 
conservative approaches (14,19). However, prolonged 
antibiotic treatments and complex dental rehabilita-
LLLT = low level laser therapy; BPT = bisphosphonate therapy; OP = osteoporosis; MM= multiple myeloma; BM = bone metastases; BPT 
= bisphosphonate therapy.
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tions may not be a reliable option for oncologic and 
compromised patients (20). These considerations lead 
to the question whether it is preferable to extract or in-
stead to restore extremely compromised teeth taking 
into account the risk of BRONJ development. 
Furthermore, the effective role of prophylactic antibi-
otic treatment has never been established. 
Antibiotic treatment we used in our BPT patients was 
chosen on the basis of literature protocols for both type 
of antibiotic (amoxicillin or an alternative broad-spec-
trum antibiotic for subjects allergic to penicillin) and 
schedule (every 12 hours starting three days before the 
surgical procedure and for 14 days) (ie, until the second 
control visit and suture removal). Dentists, oral sur-
geons and oncologists should carefully consider risks 
and benefits of possible BPT discontinuation before 
and after dental invasive procedures (17). Cessation 
of BPT may expose patients to malignancy-associated 
hypercalcaemia, failure of control of the skeletal relat-
ed events (SRE) and osteoporosis progression (21).
Our experience confirms that BPT discontinuation does 
not affect the long-term results of oral surgical proce-
dures with regard to the occurrence or worsening of 
BRONJ (22).
In the present analysis, wound healing after tooth ex-
tractions was independent from presence or absence of 
BRONJ, from the anatomic site treated (maxillary or 
mandibular), from medical conditions and from BPT 
administration modality.
According to the American Academy of Oral and Max-
illofacial Surgeons (AAOMS) and to the American 
Dental Association (ADA) guidelines, tooth extractions 
in patients under BPT should be minimally invasive, 
with limited bone and soft tissues manipulation (23). 
Muco-periosteal covering of post-extractive sockets are 
also recommended (19). 
The biostimulatory effects of LLLT performed through 
different wavelengths on the trophism of bone and mu-
cosa, both in vivo and in vitro, have been evaluated by 
several Authors, even in case of tooth extractions in 
BPT patients (24). Reported phenomena include faster 
wound healing and increased fibroblast, chondroblasts 
proliferation, collagen synthesis, stimulation of os-
teogenesis, bone cells differentiation and bone repair 
mechanisms, increasing of blood flow, stimulation of 
endothelial cells proliferation and reduction of pain (25-
27); Kucerova et al. evaluated 150 patients receiving or 
not LLLT after lower third molar extractions, demon-
strating the usefulness of laser biostimulation (28). 
Lodi et al referred that none of 23 patients under BPT 
(without BPT discontinuation) receiving tooth extrac-
tions, developed ONJ in a follow-up period of 15 months 
(29). Saia reported an occurrence of BPT-related BRONJ 
in 5 out of 60 high risk patients (8,3%) receiving tooth 
extractions. In every case BPT was suspended for 1 
month after surgery to improve bone healing. The au-
thors realized biopsies in post-extractive sockets during 
tooth extractions to assess bony features and to rule out 
asymptomatic BRONJ. In most cases they found normal 
or minimally altered bone histology and none of these 
minor alterations progressed to BRONJ. In 5 patients 
bone biopsy specimen were positive for osteomyelitis at 
baseline and were associated in all cases with the occur-
rence of clinical or radiologic BRONJ during 12 months 
of follow-up (30). 
Conclusions
The results reported in the present evaluation suggest 
that tooth extractions should not necessarily be avoided 
during BPT, most of all if there are no reliable alter-
natives. The authors conclude that the association of 
antibiotic treatment and LLLT described here and the 
suggested prophylactic protocol, has been effective, for 
reducing the incidence of BRONJ after tooth extrac-
tions and limit the spread of odontogenic infections in 
patients already debilitated by systemic disease. 
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